Laboratory and Clinical Studies on S-1108, a new oral cephem antibiotic, were carried out to evaluate its usefulness at a dose between 2 and 4 mg/kg a day for 7 to 14 days in the pediatric field. 1) Pharmacokinetic studies. S- 1108 at a dose of 2 mg/kg was administered to evaluate the pharmacokinetic parameters in 1 subject. C(max), T1/2 and AUC were 0.69 hour, 1.42 hours and 2.15 μg·hr/ml, respectively. 2) Antimicrobial activities. MICs against various clinically isolated organisms (Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Branhamella catarrhalis, Escherichia coli and Haemophilus influenzae) were determined. The MIC values of S-1006 were similler to those of cefteram, the MICs against S. pyogenes, and H. influenzae were ≤0.025 and 0.10 μg/ml, respectively. 3) Clinical studies. S-1108 was administered to patients with various pediatrics infections in 34 cases (upper respiratory tract infections: 12 cases, lower respiratory tract infections: 5 cases, urinary tract infections: 9 cases, skin and soft tissue infection: 6 cases, otitis media: 2 cases). Clinical efficacy rate was evaluated according to 'Standard of clinical evaluation in pediatrics field'. The responses were all good or excellent. 4) Side reactions. There were no serious adverse reactions in any cases. The above results suggest that S- 1108 is potent effective and safe agent in the pediatric field at a dose between 2~4 mg/kg (t.i.d.) a day.
|ジャーナル||Japanese Journal of Antibiotics|
|出版物ステータス||Published - 1993|
ASJC Scopus subject areas
- Molecular Medicine